ScripOnce a key part of its next-generation plans in cancer, Merck & Co . has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets. The two immu
ScripWho: Gilead Sciences/Merus N.V. What: Gilead is teaming with Merus to discover and develop trispecific antibodies that the companies say would target dual tumor-associated antigens. Why: Gilead f
In VivoIsrael is well known for punching above its weight in biopharma, with the country’s industry bringing innovation to the sector. In Vivo has spoken to industry leaders there to understand the impact of
ScripGilead Sciences, Inc. has partnered with Compugen Ltd. on the development and commercialization of a preclinical asset that could be a new kind of cancer immunotherapy. Gilead agreed to pay $60m up